Urashima Tetsuhiro, Tanaka Yusaku, Imanishi Kota, Kinoshita Sachika, Takei Shogo, Shimizu Yasuhiro, Yabuno Taichi, Mochizuki Yasuhisa
Department of Gastrointestinal Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.25-0455. Epub 2025 Sep 19.
Brain metastasis from esophageal cancer is rare. In particular, recurrent brain metastasis following multimodal treatment, such as preoperative chemotherapy and surgical resection, is extremely uncommon.We present a case of early brain metastasis from esophageal cancer despite achieving pathological complete response (pCR).
A middle-aged man presented with dysphagia. Upper gastrointestinal endoscopy revealed stenosis caused by an ulceroinfiltrative tumor located in the middle of the thoracic esophagus. Targeted biopsies confirmed squamous cell carcinoma. Contrast-enhanced CT revealed circumferential, irregular wall thickening with contrast enhancement, showing infiltration into the left main bronchus and enlarged lymph nodes in the paraesophageal and the left supraclavicular regions. The diagnosis was middle thoracic esophageal squamous cell carcinoma cT3br N2M0 cStage IIIB (according to the Japanese Classification of Esophageal Cancer, 12th Edition). The patient underwent chemotherapy, including 5-fluorouracil, cisplatin, and pembrolizumab, as the combined positive score exceeded 10. Following this chemotherapy with an immune checkpoint inhibitor, the tumor had regressed, and targeted biopsies revealed no malignant findings. The post-chemotherapy diagnosis was ycT3rN0M0 ycStage II, and the patient subsequently underwent thoracoscopic esophagectomy. Surgical findings showed no evidence of tumor infiltration. Postoperative histopathological examination showed no residual tumor cells in either the esophagus or resected lymph nodes, corresponding to histological response of grade 3. However, the patient presented with depression 2 months after the surgery, and abnormal behavior was shown 3 months after the surgery. Although cranial CT and MRI revealed ring-enhancing lesions in the right cerebellar hemisphere and the right frontal lobe, there was no recurrence or metastasis other than in the brain. The patient underwent resection of the frontal lobe tumor and was diagnosed with brain metastasis of esophageal cancer. Stereotactic radiation therapy and pembrolizumab were started; however, the patient died 5 months after esophagectomy due to brain metastasis progression.
5-Fluorouracil and cisplatin plus pembrolizumab therapy may allow conversion surgery in advanced esophageal cancer. However, even in patients who achieve pCR at the primary lesion, brain metastasis may occur after surgical treatment. Preoperative and postoperative surveillance for brain metastases is necessary in patients at high risk of distant metastasis, even if the local lesion is controlled.
食管癌脑转移罕见。特别是在接受多模式治疗(如术前化疗和手术切除)后出现复发性脑转移极为罕见。我们报告一例食管癌患者,尽管达到了病理完全缓解(pCR),仍发生了早期脑转移。
一名中年男性因吞咽困难就诊。上消化道内镜检查发现位于胸段食管中部的溃疡性浸润性肿瘤导致狭窄。靶向活检确诊为鳞状细胞癌。增强CT显示环形、不规则壁增厚并伴有强化,提示肿瘤浸润至左主支气管,食管旁和左锁骨上区域淋巴结肿大。诊断为胸段食管鳞状细胞癌cT3br N2M0 cIII B期(根据日本食管癌分类第12版)。由于联合阳性评分超过10,患者接受了包括5-氟尿嘧啶、顺铂和帕博利珠单抗在内的化疗。在使用免疫检查点抑制剂化疗后,肿瘤消退,靶向活检未发现恶性病变。化疗后诊断为ycT3rN0M0 ycII期,患者随后接受了胸腔镜食管切除术。手术所见未发现肿瘤浸润迹象。术后组织病理学检查显示食管及切除的淋巴结均无残留肿瘤细胞,对应3级组织学反应。然而,患者术后2个月出现抑郁,术后3个月出现异常行为。尽管头颅CT和MRI显示右侧小脑半球和右侧额叶有环形强化病变,但除脑部外无复发或转移。患者接受了额叶肿瘤切除术,被诊断为食管癌脑转移。开始进行立体定向放射治疗和帕博利珠单抗治疗;然而,患者在食管切除术后5个月因脑转移进展死亡。
5-氟尿嘧啶、顺铂联合帕博利珠单抗治疗可能使晚期食管癌患者能够接受转化手术。然而,即使原发灶达到pCR的患者,手术治疗后仍可能发生脑转移。对于远处转移高危患者,即使局部病变得到控制,术前和术后监测脑转移也是必要的。